Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

FOXO4-DRI peptide iconFOXO4-DRI46 residuesLTLRKEPASEIAQSILEEach bubble = one amino acid. Size = residue mass. Color = chemical class.

FOXO4-DRI

Beginner tier: 1 mg, EOD x3 doses (6-day pulse) · preclinical extrapolation

Anti-AgingResearch
~2-4 hours half-life (estimated)·Injection

Also known as: FOXO4-DRI, FOXO4 DRI, ES2

Aged mice regrew fur, ran longer, and showed normalized kidney function after three injections over six days. That was the 2017 Cell paper from Peter de Keizer's lab at Erasmus MC [1]. FOXO4-DRI is a D-retro-inverso peptide built to disrupt the FOXO4-p53 interaction that keeps senescent cells alive. It triggers apoptosis in those damaged "zombie" cells while leaving healthy tissue alone. No human trial has been completed. All dosing is extrapolated from mouse data using allometric scaling. Community adoption sits under 50 meaningful reports across Reddit and longevity forums, largely because cost per course runs $80 to $750 depending on dose. This is a compound you take on mechanistic faith, not measurable outcomes.

What Is FOXO4-DRI?

Three injections cleared enough senescent cells to restore kidney function in aged mice. That single finding from the Baar et al. Cell paper (2017)[1] put FOXO4-DRI on the longevity map.

FOXO4-DRI (CAS unconfirmed; molecular weight approximately 5358 Da, PubChem CID 167312269) is a 46-residue D-retro-inverso peptide derived from the p53-binding domain of FOXO4. D-retro-inverso means D-amino acids arranged in reverse order. The result is a peptide that mimics the original binding surface but resists protease degradation far better than any standard L-form sequence.

The mechanism is targeted. In senescent cells, FOXO4 binds p53 in the nucleus and blocks apoptosis. FOXO4-DRI competes for that binding site, displaces endogenous FOXO4, and frees p53 to translocate to the mitochondria. There it activates BAX and caspase-3, triggering programmed cell death. Healthy cells don't upregulate FOXO4, so they're spared. A 2025 structural NMR study confirmed the p53 TAD2 binding interaction that underpins this selectivity.

Practical use is thin. Fewer than 50 meaningful community reports exist across r/Peptides, r/longevity, and r/nootropics. Most users run a conservative 1 to 3 mg pulse (3 doses over 6 days) followed by 3 to 6 months off. That dosing sits well below the allometric human equivalent of approximately 25 mg per injection derived from the mouse protocol of 5 mg/kg IP. No consumer-grade test can measure senescent cell clearance, so there's no feedback loop to confirm anything worked. Cleara Biotech, the spinoff company, is targeting first-in-human trials of optimized derivatives (CL04177, CL04183) around 2027. Until then, FOXO4-DRI sits firmly in the experimental category.

How FOXO4-DRI Works

Senescent cells are damaged cells that stopped dividing but refuse to die. They accumulate with age and secrete a cocktail of inflammatory cytokines called the SASP (senescence-associated secretory phenotype), including IL-6 and IL-8. That chronic low-grade inflammation drives tissue deterioration and contributes to age-related disease.

What keeps these cells alive is a specific protein interaction. FOXO4 is upregulated in senescent cells and binds directly to p53 inside the nucleus. That complex sequesters p53, preventing it from doing its normal job of triggering apoptosis. Senescent cells essentially hijack the FOXO4-p53 axis to survive.

FOXO4-DRI is a cell-permeable peptide that competes with endogenous FOXO4 for the p53 binding site. Once it displaces FOXO4, phosphorylated p53 is excluded from the nucleus. It translocates to the mitochondria. There it activates the intrinsic apoptosis pathway through BAX activation and caspase-3 cleavage. The cell dies.

Selectivity comes from expression patterns. FOXO4 is selectively upregulated in senescent cells, not in healthy proliferating tissue. Baar and colleagues confirmed this in the 2017 Cell paper. A 2025 NMR structural study pinned down the exact binding interface: p53's TAD2 domain.

The D-retro-inverso backbone is the engineering trick. D-amino acids in reverse order produce a mirror-image surface that proteases can't easily degrade. Standard L-peptides last 2 to 4 hours in circulation; the DRI form likely persists 48 hours or longer, though no human PK study confirms this.

FOXO4-DRI Benefits

  • FOXO4-DRI benefits center on selective senescent cell clearance through a mechanism validated in mouse models but unconfirmed in humans.
  • Kidney function normalization (plasma urea and creatinine) in aged mice after just 3 doses over 6 days (Baar et al., Cell 2017)[1]. That was the headline finding.
  • Reversed age-related fitness decline in the same mouse study. Grip strength and running capacity improved during the off-period, weeks after the last injection.
  • Fur density restoration in aged mice provided a visible marker of tissue-level rejuvenation. Regrowth appeared during the 4 to 12 week off-period as cleared senescent niches were repopulated.
  • Cleared chemotherapy-induced senescent cells in animal models. Doxorubicin pretreatment created a high senescent cell burden; FOXO4-DRI removed it.
  • Spares healthy, non-senescent cells. The selectivity comes from FOXO4's expression pattern, which is limited to damaged cells. Huang and colleagues confirmed selective apoptosis in human chondrocyte cultures [2].
  • Protease-resistant D-retro-inverso design gives FOXO4-DRI a stability advantage over standard peptides; community users report no degradation issues with proper reconstitution and refrigerated storage within the 7 to 14 day window.

FOXO4-DRI: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 5 key studies·Research only

Selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction in cell and mouse models; mechanism confirmed by 2025 structural NMR study (p53 TAD2 binding); no human trial data

Dosing studied: 5 mg/kg IP EOD ×3 doses (mouse); allometric HED ~25 mg SC ×3 doses (70 kg human)
Read the evidence (key study, limitations)
Key Study

Baar et al., Cell 2017 (PMID 28340339): fitness restoration, kidney function normalization, fur regrowth in aged mice

Limitations

Zero completed human trials; all dosing extrapolated from mouse IP data via allometric scaling; no human PK, bioavailability, or safety data; Cleara Biotech Phase I (optimized derivatives) targeting 2027+

Community Experience
Weak
3.0/5
Based on <50 meaningful community reports across r/Peptides, r/longevity, r/nootropics

Niche use; high mechanistic interest, very low adoption; used as senolytic pulse with no measurable consumer endpoint; cost is primary adoption barrier

Community dosing: 1–3 mg SC per injection, EOD ×3 doses per course; 3–6 months off between courses
Read the reports (what users report 4, common issues 5)
What users report (4)
  • Mechanistically plausible senolytic with mouse-study validation
  • Subjective energy improvements reported by some users 2–4 weeks post-course
  • Anecdotal improved skin and hair density after 1–2 courses
  • Targeted mechanism claimed to spare healthy cells (unlike D+Q or navitoclax)
Common issues (5)
  • No consumer-grade test exists to verify senescent cell clearance: no feedback loop
  • Extremely expensive per course ($80–$750+ depending on dose)
  • Dosing unit confusion (mcg vs mg) creates 1000× error risk at the labeling and user level
  • All human benefit is speculative: zero controlled human evidence
  • Most research-grade products lack rigorous third-party purity validation for D-retro-inverso synthesis
Partially Aligned

Community has adopted the pulse-and-wait structure consistent with senolytic biology. However, community doses (1–3 mg) are far below the mouse-derived allometric HED (~25 mg). Some users still run continuous weekly protocols with no scientific basis: a misreading of how senolytics are meant to be used (pulse, then wait).

FOXO4-DRI Dosage Guide

ExtrapolatedDose extrapolated from mouse senolytic studies (Baar et al., Cell 2017) using allometric scalingSource (opens in a new tab)
LevelDose / InjectionFrequency
Beginner1 mg
EOD x3 doses (6-day pulse)Track
Moderate3 mg
EOD x3 doses (6-day pulse)Track
Aggressive25 mg
EOD x3 doses (6-day pulse)Track
Note:

The big practical issue with FOXO4-DRI is dosing unit confusion. All community protocols use milligrams (mg). Research-grade vials come in 5 mg and 10 mg sizes. The site's dosing tiers are 1 mg, 3 mg and 25 mg per injection (1,000, 3,000 and 25,000 mcg). Triple-check your math before injecting because a 1000x error between mcg and mg is a real risk that has been flagged in community discussions.

Reconstitution math for a 10 mg vial: add 2 mL bacteriostatic water to get a concentration of 5 mg/mL. For a 1 mg dose, that's 0.2 mL, which reads as 20 IU on a U-100 insulin syringe. For 3 mg, you're drawing 0.6 mL (60 IU). At the full allometric dose of 25 mg, you need multiple vials and a standard syringe instead of an insulin syringe.

For a 5 mg vial with 2 mL bacteriostatic water: concentration is 2.5 mg/mL. A 1 mg dose is 0.4 mL (40 IU). A 3 mg dose is 1.2 mL, more than a 1 mL insulin syringe holds; the 10 mg vial mix gives 3 mg in 0.6 mL.

Store reconstituted vials at 2 to 8 degrees Celsius. Use within 7 to 14 days. Lyophilized powder keeps at minus 20 degrees Celsius long-term. Don't shake during reconstitution; swirl gently. Warm the solution to body temperature before injection to reduce nodule risk.

Cycling Protocol

On Period
1 weeks
Off Period
18 weeks

Senolytic pulse: 1 week on (6 injection days) followed by 12-24 weeks off to allow full senescent cell clearance and tissue remodeling. Biomarker assessment (inflammatory markers, kidney function) recommended before repeating. Most anecdotal protocols suggest 1-3 cycles per year at most.

Calculate your FOXO4-DRI dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

FOXO4-DRI Protocols by Goal

beginnerCommunity6 active days; 3–6 months total (one course)
Active pulse
Wk 1 (6 active days)
1 mg · Every other day ×3 doses (Day 1, 3, 5) · Subcutaneous
Off period
Wk 12–24 (3–6 months)
None · N/A · N/A

Expected: Preclinical basis only: potential reduction in senescent cell burden; no measurable consumer endpoint; rely on subjective function and optional SASP cytokine panel

Monitor: SASP cytokine panel (IL-6, IL-8) + kidney function (creatinine, BUN) before course and at 8–12 weeks post-course. CBC + CRP before and at 4 weeks.

How to Inject FOXO4-DRI

  1. 1
    Reconstitute the vial

    Pull 2 mL of bacteriostatic water into a syringe and inject it slowly down the inside wall of the vial. Do not aim the stream directly at the powder. Swirl gently until dissolved. A 10 mg vial with 2 mL gives you 5 mg per mL.

  2. 2
    Calculate your dose

    For the 1 mg beginner tier from a 5 mg/mL solution, draw 0.2 mL (20 IU on a U-100 insulin syringe). For the 3 mg moderate tier, draw 0.6 mL (60 IU). The 25 mg aggressive tier is 5 mL at this strength, so it takes three 10 mg vials. That is not one insulin-syringe injection: the advanced protocol below draws it with a 10 mL syringe, and the volume can be split across sites.

  3. 3
    Prepare the injection site

    Clean with an alcohol swab. Rotate between abdomen, outer thigh, and upper arm across your 3 doses. For the 1 mg and 3 mg tiers, use a 29 to 31 gauge insulin syringe for subcutaneous injection.

  4. 4
    Inject slowly

    FOXO4-DRI is a large peptide. Pushing too fast increases nodule formation. Take 15 to 20 seconds per injection.

  5. 5
    Step 5

    Schedule your 3 doses on alternating days: Day 1, Day 3, Day 5. Morning injection on an empty stomach is the typical community protocol.

  6. 6
    After the third injection, stop

    The off-period is 3 to 6 months minimum. Your immune system needs time to process the cleared senescent cell debris through efferocytosis.

  7. 7
    Step 7

    Store the reconstituted vial at 2 to 8 degrees Celsius between doses. Discard any remaining solution after 14 days.

Mixing your own vial? Use the FOXO4-DRI reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

FOXO4-DRI Stacking Protocols

Works With

Avoid

Navitoclax (ABT-263)

Overlapping BCL-2/BCL-xL senolytic mechanism; combined use may cause excessive apoptosis and severe thrombocytopenia (navitoclax depletes platelets by killing BCL-xL-dependent megakaryocytes)

Do not combine
Immunosuppressants (cyclosporine, tacrolimus, methotrexate)

Impair macrophage-mediated efferocytosis: the immune mechanism that clears apoptotic senescent cell debris post-FOXO4-DRI; clearance failure may lead to secondary necrosis and inflammation

Do not combine
MDM2 inhibitors (nutlin, idasanutlin)

Direct p53-pathway overlap with FOXO4-DRI mechanism; combined p53 activation may cause unpredictable apoptosis in non-senescent cells

Do not combine
Concurrent chemotherapy

Chemotherapy massively increases senescent cell burden; concurrent FOXO4-DRI could trigger overwhelming senolytic load and cytokine release; also p53 interactions are complex in actively treated cancer

Do not combine

Estimated Cost

Generic / Research
~$79–$250 per 10 mg vial (research-grade market range; quality and purity vary widely)

Pricing updated 2026-04-09

FOXO4-DRI Side Effects

No human clinical safety data exists for FOXO4-DRI. Zero completed trials. Zero formal adverse event reporting. Every safety signal below comes from animal models, mechanistic reasoning, or fewer than 50 community self-reports. That limitation matters more here than for most peptides.

The most serious theoretical risk is cytokine release from rapid senolytic clearance. When large numbers of senescent cells undergo apoptosis simultaneously, the immune system must process the debris through macrophage-mediated efferocytosis. If clearance capacity is overwhelmed, apoptotic cells undergo secondary necrosis, releasing damage-associated molecular patterns (DAMPs) that trigger systemic inflammation. At the allometric human equivalent dose of approximately 25 mg, this risk is entirely uncharacterized. Even at community doses of 1 to 3 mg, some users report transient flu-like symptoms (fatigue, mild fever, joint aches) 12 to 72 hours post-injection. About 20% of community reports mention this effect.

Injection site reactions are common with FOXO4-DRI specifically because it's a 46-residue peptide with higher molecular weight. Users report nodules or lumps at the injection site that typically resolve in 24 to 48 hours. Slow injection technique, warming the solution to body temperature, and diluting in 2 mL bacteriostatic water reduces nodule formation.

The p53 pathway manipulation carries a real concern in anyone with active or undetected cancer. p53 is the most commonly mutated tumor suppressor gene. Altering its localization and activity in a setting where tumor biology is already disrupted could have unpredictable consequences. This is not a theoretical quibble; it's why Cleara Biotech's clinical program specifically targets mutant-p53 cancers with optimized derivatives.

Long-term safety is entirely unknown. Annual senescent cell turnover, chronic effects of repeated senolytic pulses, and cumulative immune system impact have never been studied in any species beyond mice.

Contraindications: pregnancy or breastfeeding (no reproductive data), active autoimmune disease, immunocompromised status (efferocytosis requires functional immunity), active cancer, severe hepatic or renal impairment, and children or adolescents (senescence plays different roles during development). Stop immediately for unexplained organ function changes, persistent injection site nodules, or any signs of systemic inflammatory response.

Common Issues & Solutions

Flu-like symptoms 12–72h post-dose (fatigue, mild fever, joint aches): expected senolytic response from senescent cell apoptosis: "zombie cell die-off" effect; reduce next course dose by 50% if severe; ensure hydration

No perceptible effects: expected and normal: no consumer biomarker measures senescent cell burden; subjective absence of effect does not indicate failure; trust the mechanistic basis or run optional SASP cytokine panel

Dosing unit confusion (mcg vs mg): ALL community protocols use milligrams (mg); research-grade vials are 5 or 10 mg; the site's tiers are 1 mg, 3 mg and 25 mg (1,000, 3,000 and 25,000 mcg); verify your math before injecting

Injection site nodule or lump: FOXO4-DRI is a large (46-residue) peptide; slow injection, warmed solution, and dilution in 2 mL BacWater reduces nodule formation; nodules typically resolve in 24–48h

Course scheduling uncertainty: minimum 3 months between courses; most researchers do 1–2 courses per year; reassess SASP and kidney function before repeating

Ask AI about this page

Ask AI for a second opinion on FOXO4-DRI dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no reproductive safety data exists
  • Active autoimmune disease: senolytic clearance may unpredictably modulate immune responses
  • Immunocompromised individuals: clearance of apoptotic cells requires functional immune system
  • Active cancer: p53 pathway manipulation could have unpredictable effects on tumor biology
  • Severe hepatic or renal impairment: impaired clearance of cellular debris
  • Known hypersensitivity to FOXO4-DRI or any excipients
  • Children and adolescents: cellular senescence plays different roles during development

Drug Interactions

  • Immunosuppressants (cyclosporine, tacrolimus, methotrexate): may impair clearance of apoptotic senescent cells
  • Chemotherapy agents: concurrent use could cause excessive senescent cell burden and amplified senolytic response
  • Anticoagulants (warfarin, heparin): theoretical risk of altered bleeding due to vascular senescent cell clearance
  • Other senolytic compounds (dasatinib, quercetin, navitoclax): overlapping mechanisms may cause excessive apoptosis
  • p53-modulating drugs (nutlins, MDM2 inhibitors): direct pathway overlap could amplify or interfere with FOXO4-DRI effects

Product Quality

Recommended Monitoring

TestWhenTarget
SASP cytokine panel (IL-6, IL-8)Before course and at 8 weeks post-courseIL-6 <2 pg/mL, IL-8 <10 pg/mL (lab-dependent reference ranges); goal is reduction from pre-course baseline
Kidney function (creatinine, BUN, eGFR)Before course and at 12 weeks post-courseCreatinine 0.7–1.2 mg/dL (male), 0.5–1.0 mg/dL (female); eGFR >60 mL/min/1.73m²
CBC with differential + CRPBefore course and at 4 weeks post-courseNot listed
Physical function assessment (grip strength, 6-minute walk or stair climb)Before course and at 12 weeks post-courseNot listed
SASP cytokine panel (IL-6, IL-8)

Primary research endpoint for senolytic efficacy: SASP reduction reflects decreased senescent cell burden; also screens for pathological inflammatory response

Kidney function (creatinine, BUN, eGFR)

Kidney function normalization was the key mouse study endpoint (Baar 2017); also monitors for any organ stress from senescent cell debris clearance

CBC with differential + CRP

Rules out systemic inflammatory response from rapid senescent cell clearance; thrombocytopenia would suggest off-target platelet effect

Physical function assessment (grip strength, 6-minute walk or stair climb)

Mirrors primary fitness endpoints from mouse studies; objective tracking; provides a structured personal data point in the absence of biomarker confirmation

FOXO4-DRI Before and After

Days 1-7

Initial dosing phase. No immediate visible effects expected. Senescent cell apoptosis begins at the cellular level. Mild injection site reactions possible. Some users report transient flu-like symptoms as senescent cells are cleared.

Weeks 2-3

Continued senolytic clearance during on-cycle. Inflammatory markers may transiently rise as senescent cells undergo apoptosis and are removed by the immune system. Energy levels and general well-being may begin to shift, though individual responses are highly variable.

Weeks 4-8
off-cycle

Post-cycle recovery and tissue remodeling. The body processes debris from cleared senescent cells. In mouse models, functional improvements (activity, organ function) became apparent during this phase. Any benefits in humans remain unconfirmed.

Months 2-4
off-cycle

Extended off-period allows full tissue adaptation. In animal studies, improvements in kidney function and physical fitness persisted well beyond the treatment window. Biomarker reassessment recommended before considering another cycle.

What to Expect

Days 1 through 6 (Active pulse): FOXO4-DRI distributes to tissues and binds the p53 TAD2 domain. It displaces endogenous FOXO4, freeing p53 to exit the nucleus and trigger apoptosis in senescent cells through BAX activation and caspase-3 cleavage. Most users feel nothing during this phase. A minority report mild headache or fatigue 24 to 48 hours post-injection. Injection site tenderness or small nodules are common and typically resolve within two days.

Weeks 1 through 4 (Early off-period): The immune system starts clearing apoptotic debris through macrophage-mediated efferocytosis. SASP cytokines like IL-6 and IL-8 may spike briefly before dropping as dead cells are processed. Some community users report improved energy and clearer skin starting around weeks 2 to 3. Responses vary widely. Transient fatigue during active immune clearance is expected.

Months 1 through 3 (Tissue remodeling): This is when mouse studies showed the payoff. Kidney function markers normalized. Fitness measures improved. Tissue progenitor cells moved into the niches left by cleared senescent cells. Community reports of improved energy, hair density, and skin quality cluster around weeks 6 to 10 post-course. None of this is controlled data.

Months 3 through 6 and beyond (Extended off-period): The mouse data showed functional gains persisting long after treatment ended. Re-dosing too early may interrupt tissue remodeling. Experienced users reassess at 4 to 6 months with SASP cytokine panels and kidney function tests before considering another course. Most protocols call for 1 to 2 courses per year at most.

Detailed Timeline: Science vs Community

Days 1–6 (Active pulse)
Science

FOXO4-DRI distributes to tissues; binds p53 TAD2; displaces FOXO4; p53 excluded from nucleus → mitochondrial translocation → BAX activation → caspase-3 cleavage → senescent cell apoptosis begins

Community

No perceptible effects for majority; minority report transient fatigue or mild headache 24–48h post-dose; injection site tenderness

Weeks 1–4 (Early off-period)
Science

Macrophage-mediated efferocytosis removes apoptotic senescent cells; SASP cytokines (IL-6, IL-8) may transiently rise then fall as dead cells are processed

Community

Some users report improved energy, clearer skin, or reduced joint discomfort beginning week 2–3; responses are highly variable and uncontrolled

Months 1–3 (Mid off-period)
Science

In mouse models, organ function improvements (kidney urea/creatinine normalization) and fitness restoration (grip strength, running capacity) emerged during this phase; tissue progenitors occupy cleared senescent niches

Community

Subjective energy, hair density, and skin quality improvements most commonly reported at 6–10 weeks post-course; anecdotal; no controlled data

Months 3–6+ (Extended off-period / reassessment)
Science

Longevity and functional gains persisted well beyond the treatment window in mouse studies; re-dosing too early may interrupt tissue remodeling

Community

Most experienced users report course-to-course re-assessment at 4–6 months; no long-term human data; subjective benefit tracking is the only available tool

Pharmacokinetics

Half-Life
3h
Bioavailability
SC: unknown (no human data); D-amino acid form expected to improve oral and systemic stability
Tmax
Estimated 1-2 hours (extrapolated from similar peptide PK profiles)
Data Confidence
low

Source: Estimated from peptide pharmacokinetics; D-retro-inverso form extends duration vs. L-peptide. No direct human PK studies available.

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours (estimated, D-retro-inverso form may extend effective duration)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
46
Sequence
LTLRKEPASEIAQSILE
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Unconfirmed (PubChem lists 2460055-10-9 as a synonym)

Who Should Consider FOXO4-DRI

  • Researchers studying cellular senescence and aging biology
  • Adults interested in experimental longevity interventions (with full informed consent)
  • Individuals with high senescent cell burden from chemotherapy or radiation (research context)
  • Aging adults experiencing accelerated tissue decline (preclinical rationale only)
  • Not suitable for the general population: preclinical compound with no human safety data

Related Peptides

What Changed for FOXO4-DRI

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C (freezer) for long-term stability; stable at 2-8°C for up to 3 months
After Reconstitution
Refrigerate at 2-8°C, use within 7-14 days
Temperature
-20°C lyophilized; 2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

No established human dose exists. The original mouse protocol used 5 mg/kg IP every other day for 3 doses. Allometric scaling to a 70 kg human gives ~25 mg per injection. Community protocols range from 1-3 mg up to the full ~25 mg. The peptide's D-retro-inverso design means it resists protease degradation far better than standard peptides.

Nobody knows for sure in humans. The D-retro-inverso backbone resists protease degradation, so it likely persists far longer than a standard L-peptide; probably 48+ hours rather than 2-4 hours. No formal human PK data has been published.

You largely don't. No consumer-grade test measures senescent cell burden. Researchers use SASP cytokine panels (IL-6, IL-8) and p16/p21 immunohistochemistry from biopsies. Subjective reports about energy, skin, or hair are entirely uncontrolled. This is a compound you take on faith and mechanism, not measurable outcomes.

Not according to the science. The published rationale calls for a brief pulse; 3 injections over 6 days; then months of rest while your immune system clears the senescent cell debris. Continuous 3-week weekly dosing has no published basis.

Partially. Cleara's lead compounds (CL04177, CL04183) are optimized derivatives targeting mutant-p53 cancers. Not the original FOXO4-DRI sequence exactly. Their first-in-human trials target 2027. Research-grade FOXO4-DRI is the original 2017 Baar et al. sequence.